Diuretic management in heart failure

Congestive Heart Failure

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Michael Felker, G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; BUMETANIDE; CONIVAPTAN; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; METOLAZONE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE;

ACUTE DECOMPENSATED HEART FAILURE; CONGESTIVE HEART FAILURE; DIURETIC THERAPY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; MAGNESIUM BLOOD LEVEL; MORBIDITY; MORTALITY; NONHUMAN; OTOTOXICITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REBOUND; REVIEW; SODIUM BLOOD LEVEL; SODIUM INTAKE; SODIUM RESTRICTION; ULTRAFILTRATION; WATER DEPRIVATION;

ANTIHYPERTENSIVE AGENTS; BLOOD VOLUME; DISEASE PROGRESSION; DIURETICS; HEART FAILURE; HUMANS; SODIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 77955153217     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00172.x     Document Type: Review

References (25)

1. Lloyd-Jones D, Adams R, Carnethon M. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):e21-e181.
2. Shah MR, Stevenson LW. Searching for evidence: refractory questions in advanced heart failure. J Card Fail 2004, 10(3):210-218.
3. Adams KF, Lindenfeld J, Arnold JM. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006, 12:1-119.
4. Jessup M, Abraham WT, Casey DE. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):1977-2016.
5. Dickstein K, Cohen-Solal A, Filippatos G. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29(19):2388-2442.
6. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341(10):709-717.
7. Juurlink DN, Mamdani MM, Lee DS. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351(6):543-551.
8. Fonarow GC, Heywood JT, Heidenreich PA. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007, 153(6):1021-1028.
9. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001, 96(3-4):132-143.
10. Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989, 36(4):682-689.
11. Kaissling B, Bachmann S, Kriz W. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am J Physiol 1985, 248(3 Pt 2):F374-F381.
12. Salvator DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database of Syst Rev 2005, 3:????-????.
13. Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? evil? a necessary evil? Circ Heart Fail 2009, 2(1):56-62.
14. Francis GS, Benedict C, Johnstone DE. Comparison of neuroendocrine activation in patients with left-ventricular dysfunction with and without congestive-heart-failure - a substudy of the Studies of Left-Ventricular Dysfunction (SOLVD). Circulation 1990, 82(5):1724-1729.
15. Francis GS, Siegel RM, Goldsmith SR. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure - activation of the neurohumoral axis. Ann Intern Med 1985, 103(1):1-6.
16. McCurley JM, Hanlon SU, Wei Sk. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004, 44(6):1301-1307.
17. Cooper HA, Dries DL, Davis CE. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999, 100:1311-1315.
18. Ahmed A, Husain A, Love TE. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006, 27(12):1431-1439.
19. Butler J, Forman DE, Abraham WT. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147(2):331-338.
20. Hasselblad V, Stough WG, Shah MR. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE Trial. Eur J Heart Fail 2007, 9(10):1064-1069.
21. Gheorghiade M, Konstam MA, Burnett JC. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297(12):1332-1343.
22. Konstam MA, Gheorghiade M, Burnett JC. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007, 297(12):1319-1331.
23. Cotter G, Dittrich HC, Weatherley BD. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008, 14(8):631-640.
24. Gottlieb SS, Brater DC, Thomas I. BG9719 (CVT-124), an A(1) adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002, 105(11):1348-1353.
25. Costanzo MR, Guglin ME, Saltzberg MT. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49(6):675-683.